CFO4Life Group’s Biolase, Inc. BIOL Stock Holding History

CFO4Life Group’s Portfolio BIOL Stock Details BIOL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-13	Closed	-$21K	–	165
2021 Q3	$21K	Hold	13	–	–	﹤0.01%	142
2021 Q2	$23K	Hold	13	–	–	0.01%	141
2021 Q1	$28K	Buy	+13	New	+$31.9K	0.01%	145

Other funds holding BIOL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EIM

Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

CFO4Life Group's BIOL Position: Q4 2021 in Review

CFO4Life Group sold out of Biolase, Inc. (BIOL) in Q4 2021, closing a stake of 13 shares — an estimated $21K sold.

CFO4Life Group first reported a position in BIOL in Q1 2021 and held it in 3 quarters. The position peaked at $28K in Q1 2021. 38 funds tracked by Wall St. Rank hold BIOL as of Q4 2021.

CFO4Life Group reported no remaining Biolase, Inc. position as of Q4 2021 after selling out during the quarter.
CFO4Life Group sold 13 Biolase, Inc. shares in Q4 2021, an estimated $21K.
CFO4Life Group first reported a position in Biolase, Inc. in Q1 2021 and held it in 3 quarters.
CFO4Life Group's Biolase, Inc. position peaked at $28K in Q1 2021.
38 funds tracked by Wall St. Rank held Biolase, Inc. as of Q4 2021.

Based on CFO4Life Group's 13F filing for Q4 2021, filed 10 Feb 2022.